Policy 1986 which inter-alia includes aspects of price control also is still in the process of being finalised. Most of the issues in this record have already been discussed in the House in August' 93 and these are being taken into account while finalising the matter.

Withdrawal of price reduction notification of Diclofenac Sodium Tablets

338. SHRI H. HANUMANTHAPPA: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that reduction in price of Diclofenac Sodium Tablets announced by Government has been withheld;

(b) the reasons for which the price reduction notification has been held in abeyance and withdrawn;

(c) what are the full facts and under what circumstances was the notification withdrawn; and

(d) who is responsible for withdrawing the notification?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (d) The price of the Voveran formulations earlier based on the adopted price of the bulk drug Diclofenac Sodium were revised on the basis of the notified price of the bulk drug.

Liability of M/s.. Cadila

339. SHRI H. HANUMANTHAPPA: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to answer to Unstarred Question 5824 given in the Rajya Sabha on 5th May, 1994 and state:

(a) whether it is a fact that liability of M/s. Cadila to pay into DPEA in respect of Dexamethasone, Oxyphenylbutazone and other drugs is over Rs. 20 crores;

(b) whether it is also a fact that liability has not been worked out due to considerations;

(c) what is the liability of M/s. Wyeth in respect of Dexamethasone that has been worked out and what are the names of other companies against whom liability is yet to be worked out; and

(d) what are the name of drugs for which liability is still to be worked out and since when the same is pending?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) Notices were issued to M/s. Cadila for submission of requisite data/details for computing the liability in respect of bulk drug Dexamethasone. As regards, bulk drug Oxyphenbutazone, the company has been asked to furnish the relevant information for computing their DPEA liability. Due to non-cooperation in submission of the data, the company has been warned that the liability will be computed on the basis of available information from whatever source and action will also be initiated under the Essential Commodities Act, 1955.

(c) The liability of M/s. Wyeth Labs in respect of Dexamethasone has been wroked out as Rs. 90.05 lakhs. To the extent information is available the data information has been called from other Companies to determine their liabilities.

(d) To the extent information is available, the names of drugs for which liability is to be worked out under Para 7(2) of DPCO 1979 are given in the enclosed Statement.

Statement

Details regarding the names of drugs for which liability is still to be worked out.

1. Oxyphenbutazone
2. Dapsone
3. Vitamin A
4. Metronidazole
5. Aspirin
6. Dexamethasone
7. Ampicillin
8. Chlorophenicol
9. Amoxycillin